166 related articles for article (PubMed ID: 20819239)
1. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma.
Vogl UM; Bojic M; Lamm W; Frischer JM; Pichelmayer O; Kramer G; Haitel A; Kitz K; Harmankaya K; Zielinski CC; Schmidinger M
BMC Cancer; 2010 Sep; 10():480. PubMed ID: 20819239
[TBL] [Abstract][Full Text] [Related]
2. The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.
Steiner T; Kirchner H; Siebels M; Doehn C; Heynemann H; Varga Z; Rohde D; Schubert J; Jocham D; Stief C; Fornara P; Hofmann R; Loening S; Roigas J
J Cancer Res Clin Oncol; 2010 Jun; 136(6):905-10. PubMed ID: 20012752
[TBL] [Abstract][Full Text] [Related]
3. Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era.
Tornberg SV; Visapää H; Kilpeläinen TP; Taari K; Järvinen R; Erkkilä K; Nisen H; Järvinen P
Scand J Urol; 2018; 52(5-6):419-426. PubMed ID: 30663485
[TBL] [Abstract][Full Text] [Related]
4. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
5. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
6. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
[TBL] [Abstract][Full Text] [Related]
7. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
10. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
[TBL] [Abstract][Full Text] [Related]
13. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
Haaker L; Tryssesoone L; Renders I; Verbiest A; Lerut E; Baldewijns M; Bourgain C; Roussel E; Van den Bulck H; Wynendaele W; Laguerre B; Rioux-Leclercq N; Oudard S; Laenen A; Debruyne PR; Albersen M; Beuselinck B
Urol Oncol; 2020 Aug; 38(8):686.e1-686.e9. PubMed ID: 32430250
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.
Klausner G; Troussier I; Biau J; Jacob J; Schernberg A; Canova CH; Simon JM; Borius PY; Malouf G; Spano JP; Roupret M; Cornu P; Mazeron JJ; Valéry C; Feuvret L; Maingon P
Clin Genitourin Cancer; 2019 Jun; 17(3):191-200. PubMed ID: 30926219
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
[TBL] [Abstract][Full Text] [Related]
16. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
Urol Oncol; 2016 Oct; 34(10):433.e1-8. PubMed ID: 27321354
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience.
Gonnet A; Salabert L; Roubaud G; Catena V; Brouste V; Buy X; Gross Goupil M; Ravaud A; Palussière J
BMC Cancer; 2019 Dec; 19(1):1182. PubMed ID: 31795959
[TBL] [Abstract][Full Text] [Related]
18. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.
Bowman IA; Bent A; Le T; Christie A; Wardak Z; Arriaga Y; Courtney K; Hammers H; Barnett S; Mickey B; Patel T; Whitworth T; Stojadinovic S; Hannan R; Nedzi L; Timmerman R; Brugarolas J
Clin Genitourin Cancer; 2019 Apr; 17(2):e263-e272. PubMed ID: 30538068
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
[TBL] [Abstract][Full Text] [Related]
20. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
Parmar A; Soliman H; Sahgal A; Bjarnason GA
Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
